Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026)

Acadia Pharmaceuticals' Raw Materials history runs 11 years deep, the most recent figure standing at $74.3 million for Q1 2026.

• In Q1 2026, Raw Materials fell 2.84% year-over-year to $74.3 million; the TTM figure through Mar 2026 stood at $74.3 million (down 2.84% YoY), while the FY2025 annual figure was $82.8 million, up 18.7% from the prior year.
• Raw Materials for Q1 2026 stood at $74.3 million, down from $82.8 million in the prior quarter.
• The five-year high for Raw Materials was $83.7 million in Q2 2025, with the low at $5.2 million in Q1 2023.
• The 5-year median for Raw Materials is $42.2 million (2024), against an average of $41.6 million.
• The sharpest annual moves came in 2023 and 2024: Raw Materials decreased 16.62% in 2023, then surged 934.36% in 2024.
• Acadia Pharmaceuticals' Raw Materials stood at $5.2 million in 2022, then soared by 501.34% to $31.3 million in 2023, then jumped by 122.73% to $69.7 million in 2024, then increased by 18.7% to $82.8 million in 2025, then retreated by 10.21% to $74.3 million in 2026.
• Business Quant data shows ACAD's Raw Materials at $74.3 million in Q1 2026, $82.8 million in Q4 2025, and $77.8 million in Q3 2025.